• Is this drug better than the standard of care?
  • Where will it fit in the competitive landscape?
  • What is the placebo response? What is the time-course of disease progression?
  • Which biomarkers predict clinical success?
  • How do different populations respond to each drug in this area?
  • What is the best dose and schedule?

qPharmetra Can Bring Meta-Analysis to Bear on these Problems

qPharmetra can help you use publically available data to glean maximum insight from this valuable “prior knowledge.” These sources include literature articles, regulatory submission documents, and conference poster presentations. Data from these sources is aggregated, placed in analysis-ready format, and then analyzed quantitatively . The result: Predictions of competitor performance, projections of your new drug based upon early study results plus the historical outcomes of previous, comparable therapies, etc., all with overt quantification of uncertainty and variability.

Your Result: The Best Use of All of the Available Knowledge to Inform your Development Decisions

With a completed meta-analysis in hand, your company has ability to predict where your drug will fall amidst competitors before you invest in your next trial. The competitive set might include long-standing standards of care, existing competitors and in some cases expected new entrants. Another application of meta-analysis can allow your company to project your drug’s profile based upon the results of other, relevant compounds’ performance. For example, it can apply other companies’ public data to leverage their learning and experience regarding biomarker relationships to clinical endpoints. This allows you to project the effects of your compound and inform your decision of whether to proceed, and if so at what investment level.